Claims for Patent: 6,426,367

Summary for Patent: 6,426,367

Title:	Methods for selectively occluding blood supplies to neoplasias
Abstract:	Disclosed are methods of selectively reducing the blood supply to a neoplastic region, such as a tumor region, thereby selectively causing necrosis of the neoplastic tissue without substantial necrosis of adjoining tissues. In particular, methods are disclosed of selectively reducing the blood supply to a neoplastic region, such as a tumor region, by causing selectively occlusion of blood vessels feeding the neoplastic region. The invention also provides methods of selectively causing anti-angiogenic action in a neoplastic region, such as a tumor region, with the result that new blood vessels are not formed to sustain the neoplasia. The methods employ intra-arterial injection of polyunsaturated fatty acids, preferably in the form of salts, preferably with a lymphographic agent, and optionally with an anti-cancer drug, and/or a cytokine. The invention also provides solutions of PUFAs, or salts of PUFAs, in combination with a lymphographic agent.
Inventor(s):	Das; Undurti N. (Norwood, MA)
Assignee:	EFA Sciences LLC (Norwood, MA)
Application Number:	09/946,129
Patent Claims:	1. A method of selectively reducing blood supply to at least a portion of a neoplastic region comprising: locating a proximal artery which carries blood to at least a portion of said region; and administering a therapeutically effective amount of a solution of at least one polyunsaturated fatty acid by intra-arterial injection into said artery, whereby said blood supply is selectively reduced without said polyunsaturated fatty acid form of an embolism or other form of physical blockage. 2. A method as in claim 1 further comprising administering a lymphographic agent by intra-arterial injection into said artery, whereby said artery and said blood supply can be visualized by angiogram. 3. A method as in claim 2 wherein said lymphographic agent is combined with said polyunsaturated fatty acid in said solution. 4. A method as in claim 2 wherein said lymphographic agent is conjugated to said polyunsaturated fatty acid. 5. A method as in claim 2 further comprising the steps of: observing the passage of said lymphographic agent into said proximal artery and said neoplastic region by angiogram; determining when said blood supply has been reduced by at least partial occlusion of blood vessels in said neoplastic region; and terminating said injection. 6. A method as in claim 5 wherein said therapeutically effective amount is an amount effective to cause at least partial occlusion of blood vessels in said neoplastic region as determined by said angiogram. 7. A method as in any one of claims 1-6 wherein said therapeutically effective amount is sufficient to cause occlusion of said artery in a period of less than one hour. 8. A method as in claim 7 wherein said therapeutically effective amount is sufficient to cause occlusion of said artery in a period of less than ten minutes. 9. A method as in claim 7 wherein said therapeutically effective amount is sufficient to cause occlusion of said artery during perfusion of said artery with said solution. 10. A method as in claim 7 herein said therapeutically effective amount is between 0.5 mg and 50 gm. 11. A method as in claim 7 wherein said therapeutically effective amount is between 250 mg and 5 gm. 12. A method as in any one of claims 1-6 wherein said polyunsaturated fatty acid is an essential fatty acid. 13. A method as in claim 12 wherein said essential fatty acid is selected from the group consisting of gamma-linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, di-homo-gamma-linolenic acid, alpha-linolenic acid, linoleic acid, and conjugated linoleic acid. 14. A method as in any one of claims 1-6 wherein said polyunsaturated fatty acid is administered in the form of a salt selected from the group consisting of a lithium salt, a sodium salt, a potassium salt, a magnesium salt, a calcium salt, a manganese salt, an iron salt, a copper salt, an aluminum salt, a zinc salt, a chromium salt, a cobalt salt, a nickel salt and an iodide. 15. A method as in any one of claims 1-6 wherein said polyunsaturated fatty acid is in the form of a fatty acid derivative selected from the group consisting of glycerides, esters, free acids, amides, phospholipids and salts. 16. A method as in any one of claims 1-6 further comprising injecting, together with or separately from the polyunsaturated fatty acid, a therapeutically effective amount of a compound selected from the group consisting of tumor necrosis factor, an anti-cancer drug, a lymphokine, and specific polyclonal or monoclonal antibodies. 17. A method as in claim 16 wherein said lymphokine is selected from the group consisting of alpha interferon and gamma interferon. 18. A method as in any one of claims 1-6 wherein said polyunsaturated fatty acid is covalently conjugated to a pharmaceutical agent chosen from the group consisting of vincristine, adriamycin, doxorubicin, cyclophosphamide, cis-platinum, L-asparaginase, procarbazine, camptothecin, taxol and busulfan.

Details for Patent 6,426,367

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2019-09-09